

Subject Index

A

- Acantholysis, drug-induced, 560
 experimental, 507-513
 biochemical, 507, 509
 enzyme activation-provoked, 509-510
 enzyme inhibition-provoked, 510-511
 immunologic, 508, 509
 thiol-provoked, 507-509
 prekeratinic, 511
- Acantholytic cells, in pemphigus
 foliaceus-like drug eruptions, in animals, 571
- Acanthosis nigricans, 4f
 clinical manifestations of, 21-22
 in dogs, 18
 endocrinopathies associated with, 14, 23
 histopathology of, 22
 history of, 21
 incidence of, 21
 malignancies associated with, 22-23, 24
 pathogenesis of, 23-24
 treatment of, 24
- Acne, in domestic animals, 204
- Acne aestivalis, 287
- Acneiform eruptions, drug-induced, 541, 542
- Acquired immunodeficiency syndrome (AIDS). *See also* HIV-positive patients
 acquired ichthyosis associated with, 27
 medications for, red face from, 316
 toxic epidermal necrolysis in, 495, 496
- Acrodermatitis, borreliosis, treatment of, 427
- Acrodermatitis chronica arthropathica, 410
- Acrodermatitis chronica atrophicans
 Borrelia burgdorferi-related, 331, 333f-334, 364, 369-375
 clinical, histologic, and serologic course after therapy, 373-374
 clinical features of, 369-370
 differential diagnosis, 372-373
- dignosis of, 372
- extracutaneous manifestations, 370-371
- features and courses, case histories illustrating, 371-372
- geographic variations of, 354-355
- histopathologic patterns of, 385-392
- historical background of, 369
- laboratory findings, 372
- neuropathy associated with, 396-397
- provocative factors, 372
- therapy for, 373
- joint and bone abnormalities associated with, 403
- Acrokeratosis paraneoplastica. *See* Bazex' syndrome
- Acrolein, 536
- Acromegaly, 53
- Actinic dermatitis
 bullous pemphigoid and, 517
 chronic, 297-305
 association with contact dermatitis, 299
 diagnosis of, 299-300
 differential diagnosis of, 300-301
 features of, 297-298
 history of, 297
 management of, 302-303
 pathogenesis of, 301-302
 predisposing factors, 298
- Actinic reticuloid syndrome, 297
- Adenocarcinoma, pulmonary, palmar dermatoglyphics associated with, 10f
- Age, as risk factor for malignancy in myositis, 62
- Agranulocytosis, drug-induced, 453, 454
- AIDS. *See* Acquired immunodeficiency syndrome
- Airborne contact dermatitis, 289
- Alcohol
 flushing reactions provoked by, 219-220
 red face from, 317
- Allergens
 facial, 291-294
- transfer of, 289-291
- Allergic contact dermatitis, 468
 red face from, in domestic animals, 206-207
- Allergic reactions, on face, 289-291
- Allergy. *See also* Drug eruptions; Drug reactions; specific type of allergy
 concept of, 438
 urticaria and angioedema and, 567-568
- Alopecia, 239
- Amoxicillin, for Lyme borreliosis, 424
- Ampicillin
 for bullous pemphigoid, 518
 bullous pemphigoid induced by, 515
 for rosacea, 230, 231
- Amyloid deposits, in lichen amyloidosis, 5f
- Amyloidosis, 33-36
 clinical manifestations of, 33-34
 differential diagnosis, 35
 histopathology of, 34-35
 incidence of, 33
 laboratory findings in, 35
 lichen, 5f
 pathogenesis of, 35
 primary, 33
 secondary, 33
 treatment of, 35-36
 veterinary, 18
- Analgesics, allergy to, 473
- Anaphylaxis. *See* Allergy
- Anesthetics, local, sensitizing, 473
- Angiitis, granulomatous, of the central nervous system, paraneoplastic, 180
- Angina bullosa haemorrhagia, drug-induced, oral, 549, 549f
- Angioedema, drug-induced, in animals, 567-568
- Animals. *See also* Veterinary dermatology
 bullous drug eruptions in, 567-574, *See also* Bullous drug eruptions
- Antibiotics. *See also* specific agent; specific type of antibiotic
 for erysipelas, 311, 312
 erythema multiforme and Stevens-

- Johnson syndrome induced by, 442, 442t, 553, 553f
fixed drug eruptions from, 443, 444t, 463
for Lyme borreliosis, 423-424
animal studies on, 425
clinical trials on, 426-428
tissue penetration by, 424
in vitro sensitivity to, 424-425
pemphigus from, 444, 444t
sensitizing, 471, 472t
for toxic epidermal necrolysis, 497
toxic epidermal necrolysis induced by, 443t, 496
in children, 552, 552f
- Antibodies. *See* Autoantibodies; specific antibody
- Anticoagulation, for toxic epidermal necrolysis, 497
- Anticonvulsants
erythema multiforme and Stevens-Johnson syndrome induced by, 442t
in children, 553
toxic epidermal necrolysis induced by, 443t, 496
in children, 552
- Antidesmoglein monoclonal antibody, 562
- Anti-DNAse B titers, in erysipelas, 309
- Antihistamines
for atopic dermatitis, 239-240
contact dermatitis from, 468
sensitizing, 473
- Anti-inflammatory agents. *See also* Nonsteroidal anti-inflammatory agents
allergy to, 473
- Anti-intercellular substance antibodies, in vesiculobullous drug eruptions, 560
- Antimalarials, for cutaneous lupus erythematosus, 258
- Antimicrobial therapy
for acrodermatitis chronica atrophicans, 387
for atopic dermatitis, 239
- Antimycotic drugs, sensitizing, 471, 472
- Antinuclear antibodies, in dermatomyositis, 266
- Antiviral agents, allergy to, 473
- Arteritis, temporal, paraneoplastic, 181
- Arthralgias, Lyme borreliosis-related, 402
- Arthritis. *See also* Rheumatoid arthritis
Lyme borreliosis-related, 401
antigen-induced, 417
chronic, 402-403
clinical features of, 402, 403
intermittent, 402
treatment of, 428
- Arthrodermatitis, 401
- Articular disease, dermatomyositis-related, 265
- ASO, in erysipelas, 309
- Atopic dermatitis, 192f, 235-242
aggravating factors in, 240-241
associated disorders, 238-239
diagnosis of, 237-238
differential, 238
epidemiology of, 236
etiology of, 235-236
facial signs associated with, 236t, 236-237
historical aspects, 235
prognosis of, 241
treatment of, 239-240
- Atopy, in domestic animals, 206
- Autoantibodies
cicatricial pemphigus induced and, 524
role in correlation of bullous pemphigoid with malignancy, 48
in vesiculobullous drug eruptions, detection of, 558, 559
- Autodromic sensorineural flushing, 216
- Autoimmune diseases
bullous, drug-induced, 558, 561
in Lyme borreliosis, 417-420
in thiol-induced pemphigus, 509
veterinary, 18
- Autonomic neural-mediated flushing, 216
- Avian hosts, for *Ixodes ricinus* and *Ixodes persulcatus*, 344t-347t, 347, 348
- Azathioprine, for dermatomyositis, 269
- B**
- B-cell, in bullous pemphigoid, 518
- B-cell lymphomas, cutaneous, 324, 325
- Baanwarth's syndrome, 353
neurologic manifestations of, 393, 394-395
- Bacterial diseases, red face from, in domestic animals, 203-204
- Bacteriologic tests, in erysipelas, 309
- Barbiturates
fixed drug eruptions from, 444t, 462, 463
porphyria cutanea tarda induced by, 536
- Basement membrane
bullous pemphigoid and, 518, 522, 524
staining, in vesiculobullous drug eruptions, 560
- Bazex' syndrome, 5f, 37-42
associated malignancy, 39
clinical manifestations of, 37-38
differential diagnosis, 39-40
histopathology of, 38-39
history of, 37
incidence of, 37
laboratory findings in, 39
pathogenesis of, 40
treatment of, 40
- Benzoyl peroxide
allergy to, 473t
for seborrheic dermatitis, 249
- Biochemical studies, in bullous pemphigoid, 518
- Blistering eruptions, drug-related. *See* Bullous drug eruptions
- Bloom's syndrome, 279
- Bone abnormalities, associated with Lyme borreliosis, 403
- Boophilus*, 336
- Borrelia anserina*, 339
- Borrelia burgdorferi*, 329-330, 339
animal reservoirs for, 342
antigenic diversity of, 342-343
antigens, detection of, 408, 409, 410, 411
clinical manifestations attributed to, 329-330, 353-354, *See also* Lyme borreliosis
discovery of, 335-338
geographic variations of, 354-355
horizontal transmission of, 339
immunopathogenesis of, 415-422
incidence and epidemiology of, 355-356
laboratory diagnostic methods for, 407-414
direct methods, 407-408
indirect methods, 408-412
laboratory findings, 330
localization of, in skin, 381-382
role in lymphocytomas and sclerotic skin lesions, 363-367, *See also* Lymphocytoma; Sclerosis
serum antibodies to, 393
specific immune response, 408-409
spirochetes, 339
staining methods, 378-381
tick vectors for, 343-348
treatment of, 330
vertical transmission of, 342
- Borrelia duttonii*, 335-336
- Borrelia garinii* sp. nov.²², 354
- Borrelia hermsii*, 337
- Borrelia theileri*, 336
- Bowen's disease, 5f, 43-46
associated malignancy, 44-45
clinical manifestation of, 43
etiology of, 44
histopathology of, 43-44
therapy for, 44
- Bromides, 542
- Bullous drug eruptions
in animals, 567-574
erythema multiforme, 568-570
fixed drug eruptions, 568, 568f
lupus erythematosus and vasculopathies, 572
pemphigus foliaceus-like drug eruptions, 571-572
photodermatitis, 572-573
spongiotic or eczematous eruptions, 572
subepidermal bullous eruption, 570-571, 571f

toxic epidermal necrolysis, 570, 570f
urticaria, angioedema, and
anaphylaxis, 567-568
commentary on, 433-435
contact dermatitis. *See* Contact
dermatitis
drug overdose-related, 444
epidemiology of, 441-446
fixed, 461-466
in children, 551, 552f
clinical features of, 461-462, 462t
diagnosis of, 463-464
epidemiology of, 461
etiology of, 443, 444t, 462-463, 463t
histopathology of, 462
immunofluorescence studies on,
559, 560
pathogenesis of, 463
therapy for, 464
historical aspects of, 437-439
immunogenetics of, 449-460
in agranulocytosis, 453, 454
in epidermolysis bullous acquisita,
455
in erythema multiforme/Stevens-
Johnson syndrome, 455
HLA and disease associations, 449-
450, 452-453
in linear IgA bullous dermatosis,
455
in mucositis, 453
in myasthenia gravis, 453
in pemphigoid, 454-455
in pemphigus, 454, 454t
proposed hypothesis for, 450-452
in systemic lupus erythematosus,
453
in systemic sclerosis, 453
in toxic epidermal necrolysis, 455
oral, 545-550, *See also* Oral lesions,
drug-induced blistering
pemphigus. *See* Bullous pemphigus
porphyria. *See* Porphyria
toxic epidermal necrolysis. *See* Toxic
epidermal necrolysis
vesiculobullous, in children, 551-554
Bullous pemphigoid, 47-52
correlation with malignancy, role of
the presence of autoantibody in,
48
drug-induced, 454, 515-520
cicatricial. *See* Cicatricial
pemphigoid
differential diagnosis of, 517, 517t
electron-beam treatment-related,
516
human immunodeficiency virus
and, 516-517
from ibuprofen, 516
inducers of, 516t, 519
interleukin-2 and, 516
oral, 548, 549

pathogenesis and new research on,
518
in patients taking multiple drugs,
517
from penicillins, 515-516
treatment of, 518
unusual problems in, 517
history of, 47-48
Bullous pemphigoid-like drug eruption.
See Subepidermal diseases,
bullous, drug-induced
Bullous pemphigus, 113-117
drug-induced, 434, 444, 444t. *See also*
Bullous pemphigoid
in children, 554, 555
versus drug-triggered pemphigus,
502-503
histopathologic criteria for
diagnosis of, 558
historical aspects of, 438
idiopathic, 507
immunofluorescence techniques for
diagnosis of, 560
immunogenetics of, 454, 454t
ocular cicatricial and pseudo-ocular
cicatricial, 454-455
oral, 546t, 547, 548f
pathomechanisms and experimental
investigations, 507-513, *See also*
Acantholysis
from penicillamine and thiol drugs,
501, 502t
from penicillin, 501, 502
relationship with genetic
predisposition and exogenous,
provoking factors, 503-504
survey on, 501-505
Burns, 285-286
first degree, 194f
Busulfan, 536

C

Calcinosis, dermatomyositis-related, 266
Cantharidin-induced acantholysis, 509,
510
Captopril
acantholysis-induced by, 510
bullous pemphigus induced by, 509,
510f
oral, 548
Cardiac disease, dermatomyositis-
related, 266
Cardiovascular drugs
cicatricial pemphigus induced by, 522
erythema multiforme and Stevens-
Johnson syndrome from, 442t
Carditis, borreliosis, treatment of, 427
Carmustine (BCNU), for cutaneous
lymphoma, 325
Cefotaxime, for Lyme borreliosis, 424
Ceftriaxone, for Lyme borreliosis, 424
Celiac disease, dermatitis herpetiformis

associated with, 48-50
Cellular immune mechanisms, of Lyme
borreliosis, 415-416
Cellulitis
bacterial, 310, 311
juvenile, in domestic animals, 209
Central nervous system
drugs acting on, erythema multiforme
and Stevens-Johnson syndrome
from, 442t
granulomatous angiitis of,
paraneoplastic, 180
Lyme disease, 417
Cephalosporins
for Lyme borreliosis, 427
pemphigus from, 502
Cerebrospinal fluid
in Baanwarth's syndrome, 394-395
Borrelia burgdorferi-specific antibodies
in, 411
Chemicals, red face from, 315
Chemotherapeutics, sensitizing, 471
Chilblains, 286
Children
facial palsy and meningitis in, in Lyme
borreliosis, 395
seborrheic dermatitis in, 249
vesiculobullous drug eruptions in, 551-
554. *See also* Vesiculobullous drug
eruptions
Chinese restaurant syndrome, flushing
in, 220
Chloramphenicol, for rosacea, 231
Churg-Strauss syndrome, paraneoplastic,
181
Cicatricial pemphigoid, drug-induced,
521-525
oral, 548
Circulating vasodilator flushing, 216-217
Climate, seborrheic dermatitis related to,
247
Clonidine (Catapres), cicatricial
pemphigus induced by, 522
Clubbing. *See* Digital clubbing
Cockayne syndrome, 279
Cold injury
chilblains, 286
frostbite, 286
urticaria, 286
Collagen bundles, atrophy of in
acrodermatitis chronica
atrophicans, 391-392
Complementation groups, in xeroderma
pigmentosum, 278
Congenital defects, red face from, in
domestic animals, 208
Contact dermatitis
airborne, 289
association of chronic actinic
dermatitis with, 299
medicament, 467-478
clinical patterns of, 467-469

- cross-sensitization in, 470, 470t
 - factors favoring development of, 467
 - occupational, 469, 470
 - sensitizers, 471-473
 - sites and dermatoses at risk, 469, 469t
 - systemic, 470-471
 - red face related to, 195f, 289-295
 - in domestic animals, 206-207
 - systemic, 195f
 - Corticosteroids
 - allergy to, 473
 - for atopic dermatitis, 239
 - for cutaneous lupus erythematosus, 258
 - for dermatomyositis, 269
 - reactions to, 441
 - pustular, 541
 - for toxic epidermal necrolysis, 498
 - Coxiella burnetii*, 335, 337
 - Cranial nerve, in Baanwarth's syndrome, 394
 - Cremophor EL, 316
 - Cutaneous paraneoplastic syndromes. *See* Paraneoplastic syndromes
 - Cutis laxa, 34
 - Cyclophosphamide
 - for dermatomyositis, 269
 - porphyria cutanea tarda induced by, 536-537
 - Cyclosporine, red face from, 315-316
 - Cyproterone acetate, for rosacea, 230, 231
 - Cysteine, 507, 508
 - Cytokine production, in Lyme borreliosis, 416
- D**
- Dapsone, 531, 538
 - Deer tick, 336-337. *See also* Lyme borreliosis; specific genus
 - Demodex canis*, 205
 - Demodicosis, 205
 - Dermabrasion, redness and crusting resulting from, 195f
 - Dermacentor rugosicauda*, 337
 - Dermacentor variabilis*, 336, 337
 - Dermal-epidermal junction, deposits at, in discoid lupus erythematosus, 253-254
 - Dermatitis herpetiformis, 48-50
 - malignancies occurring in, 50
 - lymphoma, 49-50
 - role of gluten-free diet in, 50
 - Dermatofibrosis, nodular, in dog, 4f, 17
 - Dermatoglyphics, palmar, 10f
 - Dermatomyositis, 5f-6f, 61-65, 193f
 - canine, 18
 - clinical manifestations of, 262-265
 - course and therapy of, 269-270
 - definition and classification of, 261
 - diagnosis and therapy of, 61-62
 - etiology and pathogenesis of, 261-262
 - evaluation of patient with, 268-269
 - malignancy in, 267-268
 - age as risk factor for, 63
 - clinical and laboratory correlates in, 64
 - evaluation for, 63-64
 - frequency of, 62
 - interrelationship of, 62-63
 - sites and types of, 63
 - red face from, 261-273
 - in domestic animals, 208
 - serologic testing in, 266-267
 - systemic manifestations of, 265-267
 - Dermatopathologic techniques, diagnosis of vesiculobullous drug eruptions through, 557-565. *See also* under Vesiculobullous drug eruptions
 - Dermatoses
 - associated with erythroderma, 69
 - red face related to
 - false-positive tests in, 256t
 - Dermis, acrodermatitis chronica atrophicans histopathology in, 385-387, 390, 391
 - DeSanctis-Cacchione syndrome, 277
 - Diabetes mellitus, red face related to, 317
 - Diclofenac, linear IgA disease induced by, 531
 - Diet
 - atopic dermatitis associated with, 240-241
 - gluten-free, in dermatitis herpetiformis, 50
 - Diethylcarbamazine, bullous drug eruptions induced by, 568, 568f, 572
 - Digital clubbing, 53-59
 - diagnosis of, 54
 - differential, 54-55
 - history of, 53-54
 - incidence of, 55-56
 - pathogenesis of, 56-57
 - pathology of, 56
 - treatment of, 57
 - Dipetalonema* (Wehrdickmansi) *rugosicauda*, 337
 - Dog, cutaneous paraneoplastic syndromes in, 17-18
 - metabolic necrolytic dermatitis in, 4f, 15-16
 - nodular dermatofibrosis in, 4f, 17
 - Doxycycline
 - for acrodermatitis chronica atrophicans, 373
 - for Lyme borreliosis, 424, 427-428
 - Drug eruptions
 - blistering. *See* Bullous drug eruptions
 - phototoxic, 196f
 - Drug reactions
 - cutaneous porphyria, 535-539
 - dermatomyositis linked to, 267-268
 - erythroderma related to, 69
 - patients at risk for, 441
 - pustular, 541-543. *See also* Pustular drug reactions
 - red face, 315, 316-318
 - in domestic animals, 208
 - seborrheic dermatitis, 247
 - Dwarfism, 279
- E**
- Elastase, 509, 510
 - Electron beam radiotherapy
 - bullous pemphigoid induced by, 516
 - for cutaneous lymphoma, 325
 - ELISA, in Lyme serology, 410
 - Emotions, atopic dermatitis associated with, 240
 - Enalapril
 - acantholysis induced by, 510
 - pemphigus induced by, 504
 - Encephalopathies, in Lyme borreliosis, 395, 396
 - Endocrine aspects
 - associated with acanthosis nigricans, 23, 24
 - of seborrheic dermatitis, 247
 - Endocrine tumors, cutaneous signs of, 18
 - Environmental diseases, red face from, in domestic animals, 209
 - Enzyme
 - activation, acantholysis provoked by, 509-510
 - inhibition, acantholysis provoked by, 510, 511
 - Eosinophilic granuloma complex, red face from, in domestic animals, 207
 - Eosinophilic spongiosis, 558, 560f
 - Epidemics, erythromyalgia, 76
 - Epidermal necrolysis
 - disseminated, 493
 - toxic. *See* Toxic epidermal necrolysis
 - Epidermis, acrodermatitis chronica atrophicans histopathology in, 385, 389-390
 - Epidermolysis bullosa, acquired, drug-induced, 525-526
 - Epidermolysis bullosa acquisita, drug-induced, 558
 - immunoelectron microscopy of, 561, 562
 - immunogenetics of, 455
 - Erysipelas, 196f, 307-313
 - clinical data on, 307-308
 - diagnosis of, 308-311
 - epidemiology of, 311
 - therapy for, 311-313
 - Erythema
 - in dermatomyositis, 5f
 - necrolytic migratory (hepatocutaneous syndrome), 6f
 - in domestic animals, 209
 - physical, 283-288

- burns, 285-286
- frostbite, 286
- from mechanical stimuli, 284
- pathogenesis of, 283-284
- from temperature changes, 284-285
- from ultraviolet light, 286-287
- from x-rays, 286
- reactive, erythema annulare
 - centrifugum and erythema gyratum repens, 8f, 135-139
- associated malignancy, 136
- clinical manifestations of, 135-136
- differential diagnosis of, 137
- histopathology of, 136
- history of, 135
- laboratory findings in, 136-137
- pathogenesis of, 137
- recommended evaluation of, 137
- treatment of, 137
- Erythema chronicum migrans, 353. *See also* Erythema migrans
- background of, 359-360
- Erythema exudativum multiforme, 479
- Erythema migrans, 359-362
- background of, 359-360
- Borrelia burgdorferi*-related
- histopathologic patterns of, 377-383
- treatment of, 426
- clinical considerations, 360
- cutaneous signs and symptoms, 361
- differential diagnosis, 361
- Lyme borreliosis-related, 330, 331, 332f-333f
- nomenclature for, 353
- Erythema migrans borreliosis. *See also* Erythema migrans, 353
- Erythema multiforme
- drug-induced, 434, 442-443
- in animals, 568-570
- in children, 553-554
- diagnosis of, histopathologic criteria for, 557
- immunofluorescence studies on, 559, 560
- immunogenetics of, 455
- oral, 545, 546t, 547f
- separation from toxic epidermal necrolysis, 493-494
- epidemiology of, 442
- minus and maius, drug intake and, 479-490
- clinical manifestations of, 480-481
- diagnostic criteria, 481
- etiology of, 481-483t
- histopathology of, 481
- incidence and epidemiology, 479-480
- pathogenesis of, 483-486
- Erythroderma (exfoliative dermatitis), 67-72
- associated malignancy, 68-69
- clinical manifestations of, 67
- definition of, 67
- differential diagnosis, 69-70
- histopathology of, 67-68
- incidence of, 67
- laboratory findings in, 69
- pathogenesis of, 71
- treatment of, 70
- Erythromelalgia, 73-82
- adult-onset, 76-77
- associated conditions, 75t
- classification and features of, 74t
- early-onset, 74, 76
- epidemic, 76
- history of, 73
- incidence of, 74
- nomenclature for, 73-74
- paraneoplastic, 77-79
- pathogenesis of, 75t
- treatment of, 75t
- Erythromycin
- red face from, 315
- for rosacea, 230, 231
- Erythropoietic protoporphyria, 194f
- Esophageal disease, dermatomyositis-related, 265, 270
- Estrogens, porphyria cutanea tarda induced by, 537
- Etretinate, 542
- Exanthematic necrolysis, 492, 493
- Exfoliative dermatitis. *See* Erythroderma
- Eyelids, heliotrope rash, in dermatomyositis, 5f
- Eczematous eruptions, drug-induced, 467-478
- in animals, 572
- F**
- Facial palsy, in Lyme borreliosis, 395
- Fansidar, ocular cicatricial pemphigus induced by, 523
- Fasciitis
- eosinophilic, 404
- in Lyme borreliosis, 403-404
- Fat tissue, subcutaneous, acrodermatitis chronica atrophicans
- histopathology in, 385-387
- Females, toxic epidermal necrolysis in, 495
- Fingers, clubbing of. *See* Digital clubbing
- Florid cutaneous papillomatosis. *See* Papillomatosis, florid cutaneous
- 5-Fluorouracil, red face from, 317
- Flushing disorders, 211-223
- alcohol-provoked, 219-220
- autodromic sensorineural, 216
- autonomic neural-mediated, 212-216
- causes of, 315-316
- circulating vasodilator, 216-217
- fallacious, 220
- management of, 220-221
- reastant reactions, 217-219
- Fold pyoderma (intertrigo), in domestic animals, 203
- Follicular eruptions, drug-induced, 541, 542
- Follicular plugging, in Bazex' syndrome, 5f
- Food allergy, red face from, in domestic animals, 206
- Frostbite, 286
- Fungal diseases, red face from, in domestic animals, 205
- Furosemide, acquired epidermolysis bullosa induced by, 526
- G**
- Gangrene, in Trousseau's syndrome, 10f
- Garin-Bujadoux-Baanwarth syndrome. *See* Baanwarth's syndrome
- Gene rearrangement analysis, in cutaneous lymphomas, 324
- Genetics
- acantholysis and, 511
- Bloom's syndrome and, 279
- Cockayne syndrome and, 279
- congenital erythropoietic porphyria
- Günther and, 280
- drug-induced pemphigus
- development and, 503-504, 507
- erythropoietic protoporphyria and, 279-280
- Hartnup disease and, 280-281
- red face and, in domestic animals, 208
- seborrheic dermatitis related to, 246
- xeroderma pigmentosum and, 277-278
- Giant cells, in multicentric reticulohistiocytosis, 7f
- Glucagonoma syndrome, 93-97
- clinical manifestations of, 93
- diagnosis of, 93-95
- prognosis of, 95
- treatment of, 95
- γ -Glutamyl transpeptidase (GCT), inhibition, acantholysis provoked by, 510, 511
- Gold salts, toxicity induced by, 452, 453
- Gottron's papules, in dermatomyositis, 5f
- Gottron's sign, in dermatomyositis, 262-263
- Granuloma complex, eosinophilic, red face from, in domestic animals, 207
- Granulomatous angiitis, paraneoplastic, of the central nervous system,, 180
- Griseofulvin, porphyria cutanea tarda induced by, 537
- H**
- Hair in hypertrichosis lanuginosa
- acquisita, 6f, 7f
- Hairy cell leukemia, polyarteritis nodosa associated with, 10f
- Halogen, pustular reactions induced by, 542
- Halogenoderma, 542
- Hartnup disease, 280-281

- Heliotrope eruptions, in
dermatomyositis, 5f, 262, 264
- Heme, porphyria and, 535, 536
- Henoch-Schonlein purpura,
paraneoplastic, 181
- Hepatic porphyria, drugs inducing, 535-536
- Hepatocutaneous syndrome, red face
from, in domestic animals, 209
- Herpesvirus, in erythema multiforme,
484, 485
- Hexachlorobenzene, porphyria cutanea
tarda induced by, 537
- Hippocratic fingers. *See* Digital clubbing
- HIV-positive patients
bullous pemphigoid in, 516-517
drug reactions in, 441
- HLA
in chemical and drug-induced
systemic sclerosis, 453
in drug-induced agranulocytosis, 453,
454
in drug-induced myasthenia gravis, 453
in drug-induced myositis, 453
in drug-induced pemphigoid, 454-455
in drug-induced pemphigus, 454, 454t
in drug-induced systemic
erythematosus, 453
in drug-induced toxic epidermal
necrolysis, 455
in drug-induced toxicity in
rheumatoid arthritis, 452-453
in linear IGA bullous dermatosis, 455
in Lyme arthritis, 403
in toxic epidermal necrolysis, 496
typing in pemphigus, 503
- HLA region, drug-induced bullous
disease and, 449-450, 451
- Hodgkin's disease
acquired ichthyosis associated with, 27
- Hydrocarbons, chlorinated aromatic,
porphyria cutanea tarda induced
by, 537
- Hyperpigmentation, in Bazex' syndrome,
5f
- Hyperproliferative theory, seborrheic
dermatitis related to, 248
- Hypertrichosis lanuginosa acquisita, 6f-
7f, 99-106
associated malignancy, 99-103t
clinical manifestations of, 99
differential diagnosis, 104
histopathology of, 100
history of, 99
incidence of, 99
laboratory findings in, 104
pathogenesis of, 104
recommended evaluation of, 104-105
treatment of, 104
- Hypertrophic osteoarthropathy, 53-55
diagnosis of, 54
differential, 54-55
- history of, 53-54
incidence of, 55-56
pathogenesis of, 57-58
pathology of, 56
treatment of, 57
- I**
- Ibuprofen, bullous pemphigoid induced
by, 516
- Ichthyosis, acquired, 4f, 27-29
associated disease, 27-29
clinical manifestations, 27
differential diagnosis, 28
history of, 27
incidence of, 27
- Idiopathic disorders, erythroderma
related to, 70
- IgA bullous dermatoses, linear, drug-
induced, 444, 529-523, 558
of adults, relationship of drug to,
531-532
clinical presentation of, 529, 531, 531f
diagnosis of, 529
immunogenetics of, 455
pathologic features of, 532
prognosis of, 532-533
- IgG
in acquired epidermolysis bullosa, 525,
526
in bullous pemphigoid, 518
in vesiculobullous drug eruptions, 560,
561
- IgM
Borrelia burgdorferi-specific, 410
in bullous drug eruptions, 559
- Immune complexes
Borrelia burgdorferi-specific, 411
in bullous drug eruptions, 450-452
in erythema multiforme, 483-486
in Lyme borreliosis, 416
- Immune response
to *Borrelia burgdorferi*, 408-409
in thiol-induced acantholysis, 509
- Immunoelectron microscopy, for
diagnosis of vesiculobullous drug
eruptions, 559, 561-562
- Immunofluorescence techniques
in cicatricial pemphigoid, 521, 522
for diagnosis and classification of
vesiculobullous drug eruptions,
559, 560-561, 562f
- Immunogenetics of bullous drug
eruptions, 449-460. *See also* under
Bullous drug eruptions
- Immunoglobulin-A disease, drug-
induced, 434
- Immunohistochemical techniques for
Borrelia burgdorferi staining, 379-
381
- Immunohistologic studies, in toxic
epidermal necrolysis, 496
- Immunologic factors
in bullous pemphigoid, 518
red face related to
in domestic animals, 205-208
in lupus erythematosus, 257-258
in seborrheic dermatitis, 247
- Immunologically mediated bullous
diseases, diagnosis and
classification of, 558, 559-563
- Immunopathogenesis, of Lyme
borreliosis, 415-422
- Immunophenotyping, in cutaneous
lymphomas, 323-324
- Immunoreactants, detection of, 558
- Immunosuppressive agents, for
dermatomyositis, 269-270
- Indomethacin, cicatricial pemphigus
induced by, 524
- Infection
erysipelas, 307-313
in toxic epidermal necrolysis, 497
- Insulin resistance, acanthosis nigricans
associated with, 23-24
- Interferon
 α , for cutaneous lymphoma, 326
pustular psoriasis induced by, 542
- Interleukin-1 (IL-1), 416
- Interleukin-2, in bullous pemphigoid,
516, 518
- Interleukin-2 receptor, cicatricial
pemphigus induced and, 524, 525
- Intertrigo. *See* Fold pyoderma
- Iododerma, 542
- Irritant, atopic dermatitis associated with,
240
- Irritant contact dermatitis, 467, 468, 468t
- Isoniazid, pustular reactions induced by,
541
- Isotretinoin
for rosacea, 230, 231
for seborrheic dermatitis, 249
- Ixodes dammini*, 336, 337, 338, 342
geographic distribution of, 343
host animals for, 343, 347, 348
life and seasonal cycles of, 343
prevalence of, 348
- Ixodes identatus*, 342
- Ixodes neotamiae*, 342
- Ixodes pacificus*, 338, 342
geographic distribution of, 343
host animals for, 343, 347, 348
life and seasonal cycles of, 343
prevalence of, 348
- Ixodes persulcatus*, 329, 342
avian hosts for, 344t-347t
host animals for, 343, 347, 348
mammalian hosts for, 340t-342t
reptilian hosts for, 347t
- Ixodes ricinus*, 329, 336, 337, 338
avian hosts for, 344t-347t
geographic distribution of, 343
host animals for, 343, 347, 348
life and seasonal cycles of, 343

- mammalian hosts for, 340t-342t
reptilian hosts for, 347t
transmission of *Borrelia burgdorferi* by, 343
- J**
Jo-1 antibody, in dermatomyositis, 267
Joint manifestations in Lyme borreliosis, 401-406
clinical features of, 402-404
diagnosis and differential diagnosis, 404
incidence of, 401-402
- K**
Keratinase, 510
Keratinocyte
in erythema multiforme, 485
role in erythema, 283, 284f
Keratinocyte transglutaminase (KGT), inhibition, acantholysis provoked by, 510
Keratosis pilaris, 238
Ketoconazole, for seborrheic dermatitis, 249, 250
- L**
La antibodies, in facial lupus erythematosus lesions, 257-258
Leukemia
pyoderma gangrenosum associated with, 130-131'
T-cell, cutaneous, 322, 323, 325-326
Leukocytoclastic vasculitis, cutaneous, 178, 179
Lichen amyloidosis, 5f
Lichen sclerosus et atrophicus, 365
Light microscopy, diagnosis of vesiculobullous drug eruptions through, 557
Lithium carbonate
linear IgA disease induced by, 531
pustular reactions induced by, 541, 542
Lung disease, dermatomyositis-related, 265-266, 270
Lupus erythematosus
anetoderma (elastolytic lupus erythematosus), 255
chillblain, 255
discoid, red face related to, 192f, 253-255
in domestic animals, 208
variants of, 254-255
drug-associated, in animals, 572
edematous, 254
facial, 253-260
etiopathogenesis of, 257-258
hypertrophic, 254-255
panniculitis, 255-256
subacute, 256-257
systemic
drug-induced, 453
red face related to, 193f, 208, 256
treatment of, 258
tumidus, 254
verrucous, 254-255
Lyell's syndrome. *See* Toxic epidermal necrolysis
Lyme arthritis, 353
Lyme borreliosis, 329-330, 353-357
clinical course and classification of, 353-354
clinical manifestations of, 329-330
cutaneous manifestations of, 360. *See also* Erythema migrans; Lyme disease
definition of, 423
epizootiology of *Borrelia* causing, 339-351
geographic variations of, 354-355
immunopathogenesis of, 415-422
incidence and epidemiology of, 355-356
laboratory diagnosis in, 330, 407-414
neurologic manifestations of, 393-400
rheumatic manifestations of, 401-406.
See also under Joint manifestations
therapeutic aspects of, 423-429. *See also* Antibiotics, 330
Lyme disease, 353
Lymphadenosis benigna cutis. *See* Lymphocytoma, borreliar
Lymphocytic meningoradiculitis, 353
Lymphocytoma, borreliar, 331, 333f, 363-364
clinical manifestations, 363-364
diagnosis and differential diagnosis, 364
epidemiology, 363
geographic variations of, 354-355
histopathologic patterns of, 364, 377-383
historical aspects, 363
treatment of, 264, 427, 428
Lymphoma
acquired ichthyosis associated with, 27
cutaneous, 319-328
acute T-cell, 322-323, 325
B-cell, 325
clinical features of, 320-323
diagnosis of, 323-324
epidemiology and etiology of, 319
epidermotropic, 320-321
nonepidermotropic, 322, 323
Pagetoid reticulosis, 322
staging and prognosis of, 324-325
treatment of, 325-326
variants of, 321
extracutaneous, 321-322
paraneoplastic pemphigus and, 8f
pyoderma gangrenosum associated with, 131
red face related to, 196f
- M**
Macrolides, for Lyme borreliosis, 424
Major histocompatibility complex (MHC), drug-induced bullous disease and, 449, 450
Malignancy. *See also* specific neoplasm
dermatomyositis and, 261, 267-268
hypertrichosis lanuginosa acquisita associated with, 7f
internal, cutaneous manifestations of. *See* Paraneoplastic syndrome, cutaneous
seborrheic dermatitis related to, 247
Malignant melanoma, bullae in, 518
Malpighian epithelia, morphologic changes in. *See* Acantholysis
Mange
notoedric, 204
otodectic, 205
sarcoptic, 204
Mechanical stimuli, erythema caused by, 284
Methotrexate, for cutaneous lymphoma, 325
Meningitis, in Lyme borreliosis, 395
Meningoradiculitis, lymphocytic, 353
Metabolic aspects, of seborrheic dermatitis, 247
Metabolic necrolytic dermatitis, 4f
Metals, erythema multiforme and Stevens-Johnson syndrome from, 442t
Methotrexate, 441
for dermatomyositis, 269
Metronidazole, for rosacea, 230, 231
Mice, *Borrelia burgdorferi* in, 342
Microbial theories, seborrheic dermatitis related to, 248
Microscopy. *See also* specific type of microscopy
for *Borrelia burgdorferi* detection, 407
Microtus pennsylvanicus, 336
Migratory erythema, necrolytic, 6f
Moisturizing, for atopic dermatitis, 239
Monoclonal antibodies
Borrelia burgdorferi staining and, 379, 380
in cutaneous lymphomas, 323, 325
immunolabeling of, in vesiculobullous drug eruptions, 562, 563
Monosodium glutamate (MSG), flushing reaction induced by, 220
Morphea, 365
Mucocutaneous syndrome, 493
Mucous membranes, involvement in toxic epidermal necrolysis, 494, 497
Multicentric reticulohistiocytosis. *See* Reticulohistiocytosis, multicentric
Muscle
disease, dermatomyositis-related, 264-265

- microvasculitis, paraneoplastic, 180
 - Myasthenia gravis, drug-induced, 453
 - Mycobacterium tuberculosis*, 418
 - Mycoplasma pneumoniae*, 496, 553
 - Mycosis fungoides, 320-321
 - treatment of, 325
 - Myelodysplastic syndromes, pyoderma gangrenosum associated with, 131
 - Myelofibrosis, pyoderma gangrenosum associated with, 131
 - Myeloma
 - multiple, amyloidosis associated with, 33, 34
 - pyoderma gangrenosum associated with, 131
 - Myeloproliferative disease, pyoderma gangrenosum associated with, 131
 - Myositis. *See also* Dermatomyositis
 - drug-induced, 453
 - focal, in Baanwarth's syndrome, 394
 - in Lyme borreliosis, 403
- N**
- Nailfold, in dermatomyositis, 263, 264
 - Nalidixic acid, 538
 - Nasal pyoderma, in domestic animals, 203-204
 - Nasal tip, follicular plugging and hyperpigmentation, in Bazex' syndrome, 5f
 - Neck
 - acanthosis nigricans, 4f
 - poikiloderma, in dermatomyositis, 6f
 - Necrolytic dermatitis, metabolic, canine, 4f, 15-16
 - Necrolytic migratory erythema (hepatocutaneous syndrome), in domestic animals, 209
 - Nephropathy, dermatomyositis-related, 266
 - Nerve, microvasculitis, paraneoplastic, 180
 - Neuroborreliosis, 404
 - treatment of, 427-428
 - Neurologic aspects
 - of Lyme borreliosis, 393-400
 - of seborrheic dermatitis, 247
 - Neuropathy, Lyme borreliosis-related, 419
 - Neuropsychiatric aspects, of seborrheic dermatitis, 247
 - Nodular dermatofibrosis, in dogs, 4f, 17
 - Nodules
 - fibrous, associated with acrodermatitis chronica atrophicans, 387-388, 392
 - of multicentric reticulohistiocytosis, 7f
 - Nonsteroidal anti-inflammatory agents
 - cicatricial pemphigus induced by, 522
 - erythema multiforme and Stevens-Johnson syndrome induced by, 442t
 - in children, 553
 - toxic epidermal necrolysis induced by, 443t, 496
 - in children, 552
 - Nutritional aspects, of seborrheic dermatitis, 247
 - Nutritional diseases, red face from, in domestic animals, 209
- O**
- Obesity, acanthosis nigricans associated with, 23
 - Occupational drug dermatitis, 469, 470
 - Ocular lesions, drug-induced
 - cicatricial pemphigoid, 454-455, 516, 523
 - toxic epidermal necrolysis, 498
 - Onchocerciasis, 205
 - Oral lesions, drug-induced blistering, 545-550
 - angina bullosa haemorrhagica, 549, 549f
 - drugs implicated in, 546t
 - erythema multiforme, 545, 546t, 547
 - pemphigus, 546t, 547, 548, 548f, 549
 - Stevens-Johnson syndrome, 546, 546t, 547f
 - stomatitis medicamentosa, 546t, 547, 548f
 - toxic epidermal necrolysis, 546, 546t, 547, 547f
 - Ornithodorus*, 336
 - Ornithodorus hermsi*, 336
 - Ornithodorus parkeri*, 336
 - Ornithodorus turicata*, 336
 - Ornithodoros moubata*, 335
 - Orthovoltage radiation, for cutaneous lymphoma, 326
 - Osteoarthropathy, hypertrophic, 53-55. *See also* Hypertrophic osteoarthropathy
- P**
- Pachydermoperiostosis, 53
 - Paget's disease, extramammary, 6f, 83-87
 - associated malignancy, 84-85
 - clinical manifestations of, 83-84
 - differential diagnosis, 85
 - histopathology of, 84
 - history of, 83
 - incidence of, 83
 - laboratory findings, 85
 - treatment of, 85-86
 - Pain, in Baanwarth's syndrome, 394
 - Palliative therapy, for glucagonoma syndrome, 95
 - Palmar dermatoglyphics, associated with pulmonary adenocarcinoma, 10f
 - Palms, tripe, cancer and, 165-173
 - associated malignancies, 167-169, 170t
 - clinical manifestations of, 166-167
 - differential diagnosis, 169, 170
 - histopathology of, 167
 - history of, 165
 - incidence of, 165-166
 - pathogenesis of, 171
 - recommended evaluation of, 171
 - treatment of, 170
- Pancreatic tumors
 - island cells, glucagonoma syndrome from. *See* Glucagonoma syndrome
 - superficial migratory thrombophlebitis with, 9f
- Papain, 509
- Papillomatosis, florid cutaneous, 89-91
 - associated malignancy, 89-90
 - clinical manifestations, 89
 - differential diagnosis, 90
 - histopathology of, 89
 - history of, 89
 - incidence of, 89
 - pathogenesis of, 90-91
 - treatment of, 90
- Paraneoplastic syndromes, cutaneous, 1, 4f-10f
 - acanthosis nigricans, 21-25
 - acquired ichthyosis and pityriasis rotunda, 27-32
 - amyloidosis, 33-36
 - Bazex' syndrome, 37-42
 - Bowen's disease, 43-46
 - bullous pemphigoid and dermatitis herpetiformis, 47-52, 517
 - clubbing and hypertrophic osteoarthropathy, 53-59
 - definition of, 11-13
 - dermatomyositis, 61-65
 - erythroderma and exfoliative dermatitis, 67-72
 - erythromelalgia, 73-82
 - florid cutaneous papillomatosis, 89-91
 - glucagonoma syndrome, 93-97
 - hypertrichosis lanuginosa acquisita, 99-106
 - multicentric reticulohistiocytosis, 107-111
 - Paget's disease, extramammary, 83-87
 - pemphigus, pemphigus vulgaris, and pemphigus foliaceus, 113-117
 - porphyria cutanea tarda, 119-124
 - pruritis, 125-128
 - pyoderma gangrenosum, 129-133
 - reactive erythemas, erythema annulare centrifugum and erythema gyratum repens, 135-139
 - sign of Leser-Trélat, 141-148
 - Sweet's syndrome, 149-157
 - thrombophlebitis and thrombembolic problems of malignancy, 159-163
 - tripe palms, 165-173
 - vasculitis, 175-187
 - veterinary, 15-17
- Parasitic diseases, red face from, in domestic animals, 204-205
- Paresis, in Baanwarth's syndrome, 394

- Pemphigoid. *See* Bullous pemphigoid
- Pemphigus
- bullous. *See* Bullous pemphigus
 - foliaceus, 8f, 113-114, 192f
 - foliaceus-like drug eruptions, in animals, 571-572
 - overviews of, 113-114
 - paraneoplastic, 8f, 115-116
 - associated malignancies, 115
 - clinical manifestations of, 115
 - differential diagnosis, 115-116
 - laboratory investigations in, 115
 - red face from, in domestic animals, 207-208
 - relationship to neoplasms, 114
 - vulgaris, 113
- Penicillamine
- acantholysis induced by, 507, 508, 509, 510, 510f
 - pemphigus from, 501, 502, 503
- D-Penicillamine
- bullous pemphigoid induced by, 515, 516, 518
 - bullous pemphigus induced by, oral, 548, 548f
 - cicatricial pemphigus induced by, 522
 - toxicity induced by, 452, 453, 456
- Penicillin
- for acrodermatitis chronica atrophicans, 373
 - bullous pemphigoid induced by, 515, 516, 519
 - bullous pemphigus from, 501, 502
 - for erysipelas, 311, 312
 - for Lyme borreliosis, 423-424, 425, 426, 427, 428
- Periungual telangiectasia, in dermatomyositis, 6f
- Photodermatitis, 289-290
- drug-induced, in animals, 572-573
- Photodermatoses, chronic actinic dermatitis, 297-305
- Photogenodermatoses, 275-281
- Bloom's syndrome, 279
 - Cockayne syndrome, 279
 - congenital erythropoietic porphyria (Günther), 280, 280f
 - erythropoietic protoporphyria, 279-280
 - Hartnup disease, 280-281
 - xeroderma pigmentosum, 275-279
- Photophoresis, for cutaneous lymphoma, 325-326
- Phototest, in chronic actinic dermatitis, 300
- Pityriasis alba, 238
- Pityriasis rotunda, 5f, 29-30
- associated diseases, 30
 - clinical manifestations of, 29
 - definition of, 29
 - differential diagnosis, 30
 - histology of, 29-30
 - history of, 29
 - incidence of, 29
 - laboratory tests in, 30
 - pathogenesis of, 30
 - therapy for, 30
- Pityrosporal theory, seborrheic dermatitis related to, 246
- Pityrosporon ovale, 239
- Plaque, 9f
- in cutaneous discoid lupus erythematosus, 253
 - annular atrophic, 255
- Plasma cells, in acrodermatitis chronica atrophicans, 390
- Plasminogen activator inhibitors, acantholysis and, 510
- Poikiloderma, in dermatomyositis, 6f, 263, 264
- Polyarteritis nodosa
- associated with hairy cell leukemia, 10f
 - paraneoplastic, 179-180
- Polyclonal antibodies, *Borrelia burgdorferi* staining and, 379, 380
- Polymorphism, drug-induced bullous eruptions and, 449
- Polymorphonuclear leukocytes, in pemphigus foliaceus-like drug eruptions, in animals, 571
- Porphobilinogen (PBG), 535
- Porphyria. *See also* Pseudoporphyria
- acute intermittent, 535
 - congenital erythropoietic (Günther), 280
 - drug-induced, 443, 535-539, 559
 - diagnosis of, histopathologic criteria for, 558
 - hepatic, 535-536
 - histopathology of, 537-538
 - drugs unsafe in, 444t
- Porphyria cutanea tarda, 119-124
- associated malignancy, 121-122
 - clinical manifestations of, 119
 - differential diagnosis, 121-122
 - drug and chemical-induced, 535, 536-537
 - histopathology of, 119-120
 - incidence of, 119
 - laboratory findings in, 121
 - pathogenesis of, 122
 - treatment of, 122
- Porphyria variegata, 535
- Preservatives, allergy to, 472-473
- Proteinase-antiproteinase system, disturbances, in pemphigus, 510
- Protoporphyria, erythropoietic, 194f, 279-280
- Pruritis, malignancy and, 125-128
- early history of, 125-126
 - evaluation of, 127
 - observations on, 126-127
 - recent studies on, 126
- Pseudoporphyria, drug-induced, 443, 444, 538, 559
- Pseudoscleroderma, *Borrelia burgdorferi*-related, 331
- Psoralens, 325
- Psoriasis, pustular, drug-induced, 542
- Purpura, Henoch-Schonlein, paraneoplastic, 181
- Pustular drug reactions, 541-543
- follicular and acneiform, 541-542
 - halogenoderma, 542
 - psoriasis/Reiter syndrome, 542
- PUVA, for cutaneous lymphoma, 325
- Pyoderma, in domestic animals, 203
- deep, 204
 - fold (intertrigo), 203
 - nasal, 203-204
- Pyoderma gangrenosum, 8f, 129-133
- clinical manifestations of, 129-130
 - diagnosis and evaluation of, 132
 - etiology and pathogenesis of, 132
 - histology of, 130
 - history of, 129
 - and malignancy, 130-132
 - treatment of, 132
- Pyrimethamine, ocular cicatricial pemphigus induced by, 523
- Pyridone, for seborrheic dermatitis, 249
- Pyridine derivatives, pemphigus from, 442t
- Pyrolnitrin, contact dermatitis from, 469
- R**
- Radiologic findings, in Lyme arthritis, 403
- Red face, 192f-196f
- atopic dermatitis, 235-242
 - causes of, 315-318
 - chronic actinic dermatitis, 297-305
 - contact and photocontact dermatitis, 289-295
 - cutaneous lymphoma-related, 319-328
 - dermatomyositis-related, 261-273
 - in domestic animals, 203-210. *See also* Veterinary dermatology
 - erysipelas, 307-313
 - flushing disorders, 211-223
 - historical considerations, 197-201
 - illustrations, 201
 - nomenclature, 197-198
 - older writings, 198
 - on pathogenesis of, 199-201
 - recent stories, 198-199
 - lupus erythematosus-related, 253-260
 - photogenodermatoses, 275-281
 - physical erythemas, 283-288
 - rosacea, 225-234
 - seborrheic dermatitis, 243-251
- Reflex sympathetic dystrophy, bullous pemphigoid and, 517
- Reiter's syndrome, 193f
- drug-induced, 542

- Reptilian hosts, for *Ixodes ricinus* and *Ixodes persulcatus*, 347t
- Re-PUVA, for cutaneous lymphoma, 325
- Restautant flushing reactions, 217-218
- Reticulohistiocytosis, multicentric, 7f, 107-111
- associated malignancy, 108-109
 - clinical manifestations of, 10
 - differential diagnosis, 109-110
 - histopathology of, 108
 - laboratory findings in, 109
 - treatment of, 110
- Reticulosis, Pagetoid, 322
- Retinoids, for cutaneous lymphoma, 325
- Rheumatoid arthritis, drug-induced
- toxicity in, HLA-associated, 452-453
- Rhipicephalus*, 336
- Rickettsia rickettsii*, 336, 337
- Rifampicin, porphyria cutanea tarda induced by, 537
- Rifampin, red face from, 316-317
- Ro antibodies, in facial lupus erythematosus lesions, 257-258
- Rosacea, 192f, 220, 225-234, 256t
- association with internal diseases, 226
 - clinical features of, 225-226
 - differential diagnosis, 226-227
 - etiopathogenesis of, 227-228
 - histopathology of, 226
 - treatment of, 229-230
- S**
- Scabicides, allergy to, 473t
- Scabies
- canine (sarcoptic mange), 204
 - feline (notoedric mange), 204
- Scalded skin syndrome, 553
- staphylococcal, 491
- Scleroderma, 194f
- Sclerosis
- Borrelia burgdorferi*-related, 334f, 364-366
 - associated with acrodermatitis chronica atrophicans, 389
 - morphea and lichen sclerosus et atrophicus, 365
 - in patients with acrodermatitis chronica atrophicans, 364-365
 - systemic, chemical- and drug-induced, 453
- Seasonal variation, atopic dermatitis associated with, 240
- Seborrheic dermatitis, 243-251
- diagnosis, 245
 - differential, 245-246
 - epidemiology, 243
 - etiopathogenesis, 246-248
 - of the face, 193f, 243-245
 - histopathology, 245
 - treatment of, 248-249
- Seborrheic keratosis, sign of Leser-Trélat and. *See* Sign of Leser-Trélat
- Selenium sulfide, for seborrheic dermatitis, 248, 249
- Serine proteases, 509
- Serologic tests, in erysipelas, 309
- Sézary syndrome, 321
- Shulman's syndrome, 403, 404
- Sign of Leser-Trélat, 141-148
- associated malignancies, 144, 144t
 - clinical manifestations of, 141, 144
 - differential diagnosis, 145
 - histopathology of, 144
 - history of, 141
 - incidence of, 141
 - laboratory findings in, 144-145
 - pathogenesis of, 145-146
 - recommended evaluation, 146
 - summary of case reports, 142t-143t
 - treatment of, 145
- Silver staining techniques, for *Borrelia burgdorferi*, 378-379, 380-381
- Solar dermatitis, in domestic animals, 209
- Solid tumors, pyoderma gangrenosum associated with, 131-132
- Spongiosis, eosinophilic, 558, 560f
- Spongiotic eruptions, drug-induced, in animals, 572
- Staphylococcal scalded skin syndrome, 491
- Stevens-Johnson syndrome
- drug-induced
 - in children, 553-554
 - diagnosis of, histopathologic criteria for, 557, 558
 - drugs causing, 442t, 443
 - immunogenetics of, 455
 - oral, 546, 546t, 547f
 - epidemiology of, 442
 - red face related to, 316
- Stomatitis medicamentosa, oral, 546t, 547, 548f
- Streptococcal infection, in erysipelas, 309, 310, 311, 312
- Streptococcus pyogenes*, 307, 309
- Strokelike disorders, in Lyme borreliosis, 396
- Subepidermal diseases, bullous, drug-induced, 558, 561
- in animals, 570-571, 571f
- Sulfadiazine, 572
- Sulfadoxine, ocular cicatricial pemphigus induced by, 523
- Sulphydryl drugs. *See also* Thiol drugs
- pemphigus from, 501, 502, 503
- Sulfonamide
- contact dermatitis from, 468
 - erythema multiforme from, 482
 - toxic epidermal necrolysis from, 496
- Sun sensitivity, photogenodermatoses, 275-281
- Sunburn, 286
- "Sunburn cells," 557
- Superantigens, in Lyme borreliosis, 416
- Surgery, for glucagonoma syndrome, 95
- Sweating, atopic dermatitis associated with, 240
- Sweet's syndrome, 9f, 149-157
- associated malignancies, 150-151, 152, 153t
 - clinical manifestations of, 150, 151t
 - diagnosis and differential diagnosis, 152, 154t
 - histopathology of, 150
 - history of, 149-150
 - incidence of, 150
 - laboratory findings in, 152
 - pathogenesis of, 153, 154-155
 - recommended evaluation, 155, 155t
 - treatment of, 153-154
- Synovial fluid analysis, in Lyme arthritis, 402, 403
- Synthetases, antibodies to, in dermatomyositis, 267
- Syphilis, in acrodermatitis chronica atrophicans, 373
- Systemic chemotherapy, for cutaneous lymphoma, 326
- T**
- T-cell
- in bullous drug eruptions, 451
 - cicatricial pemphigus induced and, 524, 525
 - in cutaneous lymphomas, 323-324
 - in erythema multiforme, 486
 - in Lyme borreliosis, 416
 - proliferation assays, *Borrelia burgdorferi*-specific, 411
 - in toxic epidermal necrolysis, 497
- T-cell leukemia/lymphoma, cutaneous, 322, 323
- treatment of, 325-326
- Telangiectasia, 256t
- in acrodermatitis chronica atrophicans, 390, 391
 - facial, of dwarfs, 279. *See also* Bloom's syndrome
 - periungual, in dermatomyositis, 6f, 263, 263f
- Temperature changes, erythema caused by, 284-285
- Temporal arteritis, paraneoplastic, 180
- Tetracyclines
- for Lyme borreliosis, 424
 - pseudoporphyria induced by, 538
 - for rosacea, 230, 231
- Thiol drugs. *See also* Sulphydryl drugs
- acantholysis provoked by, 507-509, 511
 - pemphigus from, 444t, 501, 502t
- Thiopronine, acantholysis induced by, 510f, 510
- Thrombocytopenia, pyoderma gangrenosum associated with, 131

- Thromboembolism. *See*
Thrombophlebitis and
thrombembolic problems of
malignancy
- Thrombophlebitis and thromboembolic
problems of malignancy, 10f, 159-
163
clinical findings in, 160
diagnosis of, 160-161
pathogenesis of, 159-160
superficial migratory, with pancreatic
cancer, 9f
treatment of, 161-162
- Tick vectors for *Borrelia burgdorferi*, 343,
348. *See also* specific genus
- Topical medications
contact dermatitis from. *See* Contact
dermatitis, medicament
for cutaneous lymphoma, 325
erythema multiforme from, 443, 482
- Toxic epidermal necrolysis, drug-
induced, 443, 443t, 493-500
in animals, 570, 571f
in children, 551, 552-553
clinical pattern of, 494
diagnosis of, histopathologic criteria
for, 557
epidemiology of, 442, 495-496
exanthematic necrolysis, 492
fixed, 492
immunogenetics of, 455
laboratory examinations in, 494-495
oral, 546t, 546, 547, 547f
overview of, 491-492
pathogenesis of, 496-497
prognosis and complications of, 497
separation from erythema multiforme,
493-494
treatment of, 497-498
- Toxic substances, seborrheic dermatitis
related to, 247
- Tranquilizers, fixed ructions from, 444t
- Transdermal drug delivery systems,
allergy and, 473
- Transpeptidases, epidermal, 510
- Trauma, red face from, 195f
- Tretinoin, red face from, 316
- Trimethoprim-sulfadiazine, 572
- Tripe palms. *See* Palms, tripe
- Trombiculidiasis, 205
- Trousseau's syndrome, 10f
- U
- Ultraviolet radiation
chronic actinic dermatitis related to,
301
erythema caused by, 286-287
- Uroporphyrin, 537
- Uroporphyrinogen, 537
- Urticaria
cold, 286
drug-induced, in animals, 567-568
- V
- Vacuoles, in acrodermatitis chronica
atrophicans, 390, 391
- Vancomycin, linear IgA disease induced
by, 531, 531f, 532
- Vasculitis, 175-187
in acrodermatitis chronica atrophicans,
390
associated malignancy, 177-181
cancer therapy and, 183
classification and nomenclature for,
175-177
in dermatomyositis, 264
histopathology of, 181-182
history of, 175
incidence of, 177, 177t
lesions mimicking, 182-183
Lyme, immunopathologic
mechanisms in, 417
pathogenesis of, 182
- Vasculopathies, drug-associated, in
animals, 572
- Vasodilator flushing, circulating, 216-217
- Vegetative syndromes, in Baanwarth's
syndrome, 394
- Vehicle constituents, allergy to, 472-473
- Vesiculobullous drug eruptions
in children, 551-554
erythema multiforme and Stevens-
Johnson syndrome, 544f, 553-554
fixed drug eruptions, 551
pemphigus, 544, 555
toxic epidermal necrolysis (Lyell's
syndrome), 551-553
- dermatopathologic approach to
diagnosis, 557-565
histopathologic criteria for, 557-558,
560f
immunoelectron microscopy, 561-
562, 563f
immunofluorescence techniques,
559, 560-561
immunopathologic criteria for, 558-
559
monoclonal antibody
immunolabeling, 562, 563, 564
- Veterinary dermatology
cutaneous paraneoplastic syndromes
metabolic necrolytic dermatitis, 15-
16
nodular dermatofibrosis, 17
red face in domestic animals, 203-210
bacterial diseases, 203-204
congenital and hereditary defects,
208-209
environmental diseases, 209
fungal diseases, 205
immunologic diseases, 205-208
juvenile cellulitis, 209
necrolytic migratory erythema
(hepatocutaneous syndrome), 209
nutritional diseases, 209
parasitic diseases, 204-205
- Viral antigens, in erythema multiforme,
485
- W
- Western blot in Lyme serology, 409-410
- Woringer-Kolopp disease, 323
- X
- X-rays
erythema caused by, 286
- Xeroderma pigmentosum, 194f, 275-279
clinical findings in, 275-277
complementation groups in, 278
genetic factors and epidemiology, 277-
278
treatment of, 278-279
- XP genes, in xeroderma pigmentosum,
277, 278
- Z
- Zinc-responsive dermatosis, 209